Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06502483 · ClinicalTrials.gov registry record · NA

PRISM for Depression and Anxiety in Young Adults With Cancer

A NA study of Depression and Anxiety, sponsored by Dana-Farber Cancer Institute.

Active
Registry status
NA
Development phase
15
Enrollment target
1
Study location

NCT06502483 is a NA study of Depression and Anxiety that is active but no longer recruiting, run by Dana-Farber Cancer Institute. The registered enrollment target is 15 participants, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06502483, a NA study of Depression and Anxiety, is active but no longer recruiting, sponsored by Dana-Farber Cancer Institute.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
15 participants
Enrollment target
1
Study location

Study Summary

This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience. The name of the intervention used in this research study is: -Promoting Resilience in Stress Management (PRISM) Program

Interventions

  • BEHAVIORAL Promoting Resilience in Stress Management Program

Study Locations (1)

Massachusetts

  • Dana-Farber Cancer Institute - Brighton

Trial Details

FieldValue
Enrollment Target 15 participants
Start Date 2024-09-06
Est. Completion 2026-02-01
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT06502483

The ClinicalTrials.gov registry entry for NCT06502483 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 786-participant average among 679 other Depression trials with a reported enrollment target (98% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 8 conditions, with Depression appearing as the primary indexed condition, and to 1 intervention - of which Promoting Resilience in Stress Management Program is the first listed.

NCT06502483 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06502483 about?

NCT06502483 is a clinical study titled "PRISM for Depression and Anxiety in Young Adults With Cancer". This research study is being done to test the feasibility of an existing supportive program (PRISM) to address psychological symptoms (i.e., depressive and anxiety symptoms) that young adult participants diagnosed with cancer or desmoid tumor may experience. The name of the intervention used in thi...

What is the current status of trial NCT06502483?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 15 participants. The study started on 2024-09-06. Estimated completion is 2026-02-01.

What conditions does trial NCT06502483 study?

This clinical trial studies the following conditions: Depression, Anxiety, Anxiety Disorders, Depressive Disorder, Depression, Anxiety.

What interventions are being tested in trial NCT06502483?

The interventions under investigation include: Promoting Resilience in Stress Management Program (BEHAVIORAL).

Who is sponsoring clinical trial NCT06502483?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06502483 being conducted?

This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Depression

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.